DEAL DETAILS
|
Eris Lifesciences Limited | Acquisition of the Indian branded formulations business of Biocon Biologics Limited |
Khaitan & Co advised Eris Lifesciences Limited on its acquisition of the branded formulations business of Biocon Biologics Limited in India for a total consideration of INR 1,242 Crores. The acquisition helps augment and expand the business of Eris Lifesciences in the branded sterile injectibles market and enter into the oncology and critical care segments in India. As part of this deal, Eris Lifesciences Limited has also signed a 10-year supply agreement with Biocon Biologics Limited.
The team was led by Kalpana Unadkat (Partner) with assistance from Kevin Shah (Principal Associate), and Sushmita Som (Associate).
The Firm acted as legal counsel for Eris Lifesciences Limited and assisted in drafting, reviewing, negotiating and finalising the transaction documents.
